The invention belongs to the field of biomarkers, and particularly relates to screening and application of a biomarker related to an AD
cell model constructed by A beta induction. The biomarker comprises one or a combination of more of the following components:
Cysteine Desulfurase, mistoral, the code is NFS1, NADH (
Nicotinamide Adenine Dinucleotide)
dehydrogenase [
ubiquitin] 1 alpha subcomplex
subunit 9, mitochondrial, the code is NDUFA 9; 3-hydroxyacyl-CoA
dehydrogenase type-2, and the code is HSD17B10;
Cytochrome c oxidase
subunit NDUFA4, and the code is NDUFA4; NADH-ubiquinone
oxidoreductase 75 kDa
subunit, mitochondrial, the code is NDUFS1;
Succinate dehydrogenase[ubiquinone]iron-
sulfur subunit, mitochondrial, the code is SDHB; NADH
dehydrogenase[ubiquinone]iron-
sulfur protein 4, mitochondrial, the code is NDUFS4;
Lipoprotein lipase, the code is LPL; NADH dehydrogenase[ubiquinone]1 alpha subcomplex subunit 5, the code is NDUFA5. A
proteomics method is adopted, a group of biomarkers are found in an A beta-induced AD
cell model, and the biomarkers are found to be mutually matched in the A beta-induced AD
cell model and jointly play an important role. The method for detecting the AD
cell model constructed through A beta induction is enriched, and a new target is provided for
clinical research.